GH therapy has been introduced in several syndromic disorders with short stature, i.e., Noonan syndrome, Prader–Willi syndrome (PWS), and Silver–Russell syndrome (SRS), while there are limited data on the effect of rhGH treatment on children with short stature and skeletal dysplasia (29–31). Here, GH1 is linked to Prader-Willi syndrome.